SCHEMBL1421362

SCHEMBL1421362

COC(=O)c1ccc(N2C(=O)C(=Cc3ccc(OC)c(O)c3)SC2=S)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.60
HSD17B3 P37058 1/20 0.59
HSPD1 P10809 1/20 0.59
HSPE1 P61604 1/20 0.59
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
ALDH1A1 P00352 1/20 0.58
LMNA P02545 1/20 0.58
MAPT P10636 1/20 0.58
OPRK1 P41145 2/20 0.56
ATM Q13315 1/20 0.56
CACNA1B Q00975 1/20 0.55
APBA1 Q02410 1/20 0.55
GRK6 P43250 1/20 0.55
S1PR1 P21453 1/20 0.54
S1PR3 Q99500 1/20 0.54
POLB P06746 2/20 0.53
DUSP26 Q9BV47 1/20 0.52
DUSP22 Q9NRW4 3/20 0.52
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421361 1.00 PDE4B (0.60) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL1421357 1.00 PDE4B (0.60) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL5991606 0.83 TDP1 (0.72) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL5461746 0.81 HSPD1 (0.70) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL5461744 0.81 HSPD1 (0.70) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL1421134 0.80 MEN1 (0.61) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL1421130 0.80 MEN1 (0.61) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL1421133 0.80 MEN1 (0.61) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL13236133 0.80 HSPD1 (0.75) PDE4BHSD17B3HSPD1HSPE1MEN1
SCHEMBL1421493 0.79 KMT2A (0.85) PDE4BHSD17B3MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US claimed
EP-2296476-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION Microbiotix, Inc. (US) 2011-03-23 EP claimed
WO-2009142720-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2009-11-26 WO claimed
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US disclosed
EP-2296476-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION Microbiotix, Inc. (US) 2011-03-23 EP disclosed
WO-2009142720-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION BLVRB, TFPI, FOSB PDE4B 3530/4885HSD17B3 3251/4885HSPD1 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.